Search results for "Major Article"

showing 4 items of 14 documents

A Multiplex Panel of Plasma Markers of Immunity and Inflammation in Classical Kaposi Sarcoma

2014

Kaposi sarcoma (KS) risk is affected by perturbed immunity. Herein, we compared plasma from 15 human immunodeficiency virus (HIV)–negative classic KS cases to plasma from 29 matched controls, using a multiplex panel of immunity markers. Of 70 markers, CXCL10 (IP-10), sIL-1RII, sIL-2RA, and CCL3 (MIP-1A) were strongly and significantly associated with KS, after adjustment for age and smoking status. These and previous observations are consistent with a tumor-promoting role for these cytokines, particularly CXCL10, but the small sample size and case-control design preclude firm conclusions on KS risk or pathogenesis. Larger, well-designed prospective studies are needed to better assess the as…

Malemedicine.medical_treatmentInflammationBiologySettore MED/42 - Igiene Generale E ApplicataPathogenesisKaposi SarcomaPlasma Markers of InflammationMajor Articles and Brief ReportsImmunitymedicineHumansImmunology and AllergyProspective cohort studySarcoma KaposiInflammationCase-control studyvirus diseasesPlasma Markers of Immunitymedicine.diseaseSquamous intraepithelial lesionInfectious DiseasesCytokineItalyCase-Control StudiesImmunologySarcomamedicine.symptomBiomarkers
researchProduct

Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

2021

Abstract Background Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). Methods This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. Results We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range,…

PNEUMONIAMalevirusesmedicine.medical_treatmentseasonal human coronavirusHematopoietic stem cell transplantationmedicine.disease_causeDISEASElaw.inventionCoronavirus OC43 HumanCLINICAL CHARACTERISTICSlawCoronavirus 229E HumanRisk FactorsImmunology and AllergyChildRespiratory Tract InfectionsNL63 INFECTIONSCoronavirusOUTCOMESRespiratory tract infectionsSYNCYTIAL VIRUSHazard ratioHematopoietic Stem Cell Transplantationvirus diseasesupper and lower respiratory tract diseaseHCoV-NL63HCoV-229Erespiratory systemMiddle AgedIntensive care unitHospitalizationimmunocompromisedsurgical procedures operativeInfectious Diseasesmedicine.anatomical_structureAcademicSubjects/MED00290Child PreschoolCohortFemaleSeasonsCoronavirus InfectionsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]allogeneic hematopoietic stem cell transplantation; community-acquired respiratory virus; HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; immunocompromised; immunodeficiency score index; multiplex PCR assay; seasonal human coronavirus; upper and lower respiratory tract diseaseAdultmedicine.medical_specialtyHCoV-OC43AdolescentDIAGNOSISCHINAHCoV-HKU1BetacoronavirusAll institutes and research themes of the Radboud University Medical Centerstomatognathic systemInternal medicinemedicineMajor ArticleRHINOVIRUSHumansallogeneic hematopoietic stem cell transplantationAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryInfantmultiplex PCR assayTransplantationCoronavirus NL63 HumanPARAINFLUENZA VIRUSbusinessimmunodeficiency score indexRespiratory tract
researchProduct

SARS-CoV-2 outbreak in medical employees in a large urologic department: Spread, containment and outcome.

2021

Background The SARS-CoV-2 pandemic presents an unprecedented challenge to health care systems worldwide. Data on SARS-CoV-2 transmission in a hospital is rare and outbreaks among health care professionals are complex to control. Material and Methods Over the course of 6 consecutive weeks we recorded data on an exponential outbreak of SARS-CoV-2 within our department. We reconstructed the assumed route of the spread of infection, and the employees’ acute and late symptoms. Increasing preventive measures (mandatory face masks, intense training in hygiene, physical distancing whenever possible, and termination of visits from outside the hospital) were implemented. Results Within 6 weeks, 13 em…

medicine.medical_specialtyEpidemiologymedia_common.quotation_subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Health PersonnelDisease Outbreaks03 medical and health sciences0302 clinical medicineHygienePandemicHealth careMajor ArticleMedicineHumans030212 general & internal medicinePandemicsmedia_common0303 health sciencesViral spreadPandemic030306 microbiologybusiness.industryTransmission (medicine)Medical settingSARS-CoV-2Health PolicyPublic Health Environmental and Occupational HealthOutbreakCOVID-19Face masksInfectious DiseasesEmergency medicinebusinessAmerican journal of infection control
researchProduct

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing

2020

Abstract Background Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. Methods A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46…

medicine.medical_specialtyceftolozane/tazobactammedicine.medical_treatmentCRRTTazobactamEnterobacteralesEnterobacteraleInternal medicineCRRT; ESBL; Enterobacterales; ceftolozane/tazobactam; septic shockMajor ArticlemedicineClinical endpointRenal replacement therapybusiness.industrySeptic shockRetrospective cohort studyOdds ratiomedicine.diseaseCeftolozane/tazobactam; CRRT; Enterobacterales; ESBL; Septic shockAcademicSubjects/MED00290Infectious DiseasesOncologyESBLseptic shockCeftolozanebusinessEmpiric therapymedicine.drugOpen forum infectious diseases
researchProduct